CENPO is Associated with Immune Cell Infiltration and is a Potential Diagnostic and Prognostic Marker for Hepatocellular Carcinoma

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2022 Oct 3

PMID 36187159

Authors

Kun He

Mengyi Xie

Jingdong Li

Yi He

Yaolin Yin

Affiliations

Soon will be listed here.

Abstract

Purpose: To examine the expression, clinical significance, and potential regulatory mechanism of centromere protein O (CENPO) in hepatocellular carcinoma (HCC).

Methods: CENPO expression in pan-cancer was studied using the TCGA-GTEx database, in HCC and normal liver tissues using the GEO and TCGA databases, and in clinical HCC samples by RT-qPCR. The diagnostic value of CENPO was assessed using receiver operating characteristic curves. Univariate and multivariate regression analyses of factors associated with HCC prognosis were performed. CENPO function and its mechanism in HCC were explored using GO, KEGG, and GSEA analyses of differentially expressed genes (DEGs). Association of CENPO expression with immune cell infiltration and immune checkpoint-associated molecules was conducted using TCGA data and the TIMER2.0 database. Relationships between expression and DNA methylation were analyzed using the UALCAN and cBioPortal databases. CENPO expression in HCC cell lines was detected using RT-qPCR.

Results: is upregulated in most cancers, including HCC and cell lines, and is a potential biomarker for HCC diagnosis (AUC = 0.936, 95% CI: 0.911-0.960). Higher expression was associated with poorer outcomes in patients with HCC (OS, p = 0.004; DSS, p = 0.002; PFI, p < 0.001), and CENPO was an independent predictor of factors influencing overall survival in HCC. DEGs between samples with high and low levels were enriched in various biological processes, including activation of the G2M checkpoint and other signaling pathways, while expression correlated with HCC immune cell infiltration and immune checkpoint-associated molecules, as well as promoter methylation (p < 0.001).

Conclusion: In HCC and cell lines, is overexpressed, a potential diagnostic marker and an indicator of poor prognosis. may regulate HCC development by influencing nuclear division and tumor immune infiltration and is regulated by methylation, making it a potential target for HCC immunotherapy.

Citing Articles

Recent updates of centromere proteins in hepatocellular carcinoma: a review.

Yang Z, Chen W, Liu Y, Niu Y Infect Agent Cancer. 2025; 20(1):7.

PMID: 39915786 PMC: 11800463. DOI: 10.1186/s13027-024-00630-2.

The role of lnc‑MAPKAPK5‑AS1 in immune cell infiltration in hepatocellular carcinoma: Bioinformatics analysis and validation.

Hu X, Wang D, Chen J, Liang B, Zhang L, Qin P Oncol Lett. 2025; 29(3):141.

PMID: 39850723 PMC: 11755229. DOI: 10.3892/ol.2025.14887.

High expression levels of centromere protein O participates in cell proliferation of human ovarian cancer.

Si L, Sun G, Liu Z, Gu S, Yan C, Xu J J Ovarian Res. 2024; 17(1):126.

PMID: 38890751 PMC: 11184697. DOI: 10.1186/s13048-024-01452-x.

The Correlation of Centromere Protein Q with Diagnosis and Prognosis in Hepatocellular Carcinoma.

He K, Xie M, Gao X, Wang H, Li J Pharmgenomics Pers Med. 2024; 17:271-288.

PMID: 38827182 PMC: 11141762. DOI: 10.2147/PGPM.S456965.

High Expression of DNTTIP1 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma.

Wang X, Li W, Lou N, Han W, Hai B, Xiao W Pharmgenomics Pers Med. 2023; 16:1-14.

PMID: 36636625 PMC: 9831534. DOI: 10.2147/PGPM.S382843.

References

Wei J, Huang K, Yang C, Kang C . Non-coding RNAs as regulators in epigenetics (Review). Oncol Rep. 2016; 37(1):3-9. DOI: 10.3892/or.2016.5236. View

DeNardo D, Barreto J, Andreu P, Vasquez L, Tawfik D, Kolhatkar N . CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009; 16(2):91-102. PMC: 2778576. DOI: 10.1016/j.ccr.2009.06.018. View

He P, Hu P, Yang C, He X, Shao M, Lin Y . Reduced expression of CENP-E contributes to the development of hepatocellular carcinoma and is associated with adverse clinical features. Biomed Pharmacother. 2019; 123:109795. DOI: 10.1016/j.biopha.2019.109795. View

Goldman M, Craft B, Hastie M, Repecka K, McDade F, Kamath A . Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38(6):675-678. PMC: 7386072. DOI: 10.1038/s41587-020-0546-8. View

Li Y, Zhu Y, Fang J, Li W, Li S, Liu X . Apoptin Regulates Apoptosis and Autophagy by Modulating Reactive Oxygen Species (ROS) Levels in Human Liver Cancer Cells. Front Oncol. 2020; 10:1026. PMC: 7344208. DOI: 10.3389/fonc.2020.01026. View

Tiong L, Maddern G . Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011; 98(9):1210-24. DOI: 10.1002/bjs.7669. View

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

Earnshaw W . Discovering centromere proteins: from cold white hands to the A, B, C of CENPs. Nat Rev Mol Cell Biol. 2015; 16(7):443-9. DOI: 10.1038/nrm4001. View

Liu Y, Xiong S, Liu S, Chen J, Yang H, Liu G . Analysis of Gene Expression in Bladder Cancer: Possible Involvement of Mitosis and Complement and Coagulation Cascades Signaling Pathway. J Comput Biol. 2019; 27(6):987-998. DOI: 10.1089/cmb.2019.0237. View

10.

Pinato D, Guerra N, Fessas P, Murphy R, Mineo T, Mauri F . Immune-based therapies for hepatocellular carcinoma. Oncogene. 2020; 39(18):3620-3637. PMC: 7190571. DOI: 10.1038/s41388-020-1249-9. View

11.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q . TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48(W1):W509-W514. PMC: 7319575. DOI: 10.1093/nar/gkaa407. View

12.

Guo Y, Hu J, Zhao Z, Zhong G, Gong J, Cai D . Identification of a Prognostic Model Based on 2-Gene Signature and Analysis of Corresponding Tumor Microenvironment in Alcohol-Related Hepatocellular Carcinoma. Front Oncol. 2021; 11:719355. PMC: 8503534. DOI: 10.3389/fonc.2021.719355. View

13.

Hodo Y, Honda M, Tanaka A, Nomura Y, Arai K, Yamashita T . Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C. Clin Cancer Res. 2013; 19(7):1827-37. DOI: 10.1158/1078-0432.CCR-12-1641. View

14.

Li X, Li Y, Xu A, Zhou D, Zhang B, Qi S . Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma. Oncoimmunology. 2021; 10(1):1992104. PMC: 8525945. DOI: 10.1080/2162402X.2021.1992104. View

15.

Angeloni A, Bogdanovic O . Enhancer DNA methylation: implications for gene regulation. Essays Biochem. 2019; 63(6):707-715. DOI: 10.1042/EBC20190030. View

16.

Ma H, Qu J, Luo J, Qi T, Tan H, Jiang Z . Super-Enhancer-Associated Hub Genes In Chronic Myeloid Leukemia Identified Using Weighted Gene Co-Expression Network Analysis. Cancer Manag Res. 2020; 11:10705-10718. PMC: 6934127. DOI: 10.2147/CMAR.S214614. View

17.

Kaowinn S, Seo E, Heo W, Bae J, Park E, Lee S . Cancer upregulated gene 2 (CUG2), a novel oncogene, promotes stemness-like properties via the NPM1-TGF-β signaling axis. Biochem Biophys Res Commun. 2019; 514(4):1278-1284. DOI: 10.1016/j.bbrc.2019.05.091. View

18.

Zeng H, Shen Y, Hirachan S, Bhandari A, Zhang X . Pan-cancer investigation of CENPK gene: clinical significance and oncogenic immunology. Am J Transl Res. 2022; 13(12):13336-13355. PMC: 8748151. View

19.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

20.

Zeng Z, Jiang X, Pan Z, Zhou R, Lin Z, Tang Y . Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma. Aging (Albany NY). 2021; 13(19):22802-22829. PMC: 8544325. DOI: 10.18632/aging.203574. View